Germany's Intu Diagnostics raises €1.1M for lab-free infection tests
What's the deal? Intu DiagnosticsDealroom has a profile for this one. Try Dealroom →, a German developer of infectious disease tests, has raised €1.1 million ($1.2 million) in seed funding.
The company is building lab-free diagnostics that bring testing closer to patients, cutting the need for centralised labs.
Why now? Demand for fast, decentralised testing has surged since the pandemic exposed the limits of lab-dependent systems.
The bridge round gives Intu runway to advance its technology as healthcare shifts toward point-of-care solutions.
What could go wrong? Diagnostics is a slow, heavily regulated field, and small rounds can force startups back to fundraising quickly.
Intu must also prove its tests match lab accuracy to win clinical trust.
The signal: Intu positions itself as an early-stage venture blending AI-powered diagnostics with lab-free testing, a combination investors increasingly view as central to faster, more accurate disease detection outside centralised labs. The modest bridge round reflects the cautious, milestone-driven funding typical of a heavily regulated diagnostics field.
Read more: EU-Startups
Image credit: umseas
